GPC3 and hepatocellular carcinoma: Following proof-of-concept validation with the murine anti-GPC3 antibody, we used the same conjugation and validation workflow to evaluate a chimeric anti-GPC3 antibody, ET58, that is currently being evaluated in clinical trials for cell-based therapy of HCC.